Arthritis Drug Tocilizumab Gets FDA EUA for Severe COVID-19 Arthritis Drug Tocilizumab Gets FDA EUA for Severe COVID-19
For patients hospitalized with COVID-19, tocilizumab plus standard care has been shown to cut the risk for death, shorten hospitalization time, and reduce the need for mechanical ventilation.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 25, 2021 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

Roche's Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous Actemra/RoActemra® (tocilizumab) for the treatment of COVID-19 in hospitalised adults and paediatric patients (two years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). (Source: World Pharma News)
Source: World Pharma News - June 25, 2021 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Roche ’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children
Basel, 25 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous Actemra/RoActemra ® (tocilizumab) for the treatment of COVID-19 in hospitalised adults and paediatric patients (two years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The E UA is based on results from four randomised, controlled studies that evaluated Actemra/RoActemra for the treatment of COVID-1...
Source: Roche Investor Update - June 25, 2021 Category: Pharmaceuticals Source Type: news

Roche ’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children
Basel, 25 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous Actemra/RoActemra ® (tocilizumab) for the treatment of COVID-19 in hospitalised adults and paediatric patients (two years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The E UA is based on results from four randomised, controlled studies that evaluated Actemra/RoActemra for the treatment of COVID-1...
Source: Roche Media News - June 25, 2021 Category: Pharmaceuticals Source Type: news

US approves Roche drug for emergency use against severe Covid-19
Though rising vaccinations in places such as Europe and the United States are reducing hospitalizations for COVID-19, Actemra is still being deployed for certain patients who land in the hospital. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 25, 2021 Category: Pharmaceuticals Source Type: news

CRP Level May Help Guide Use of Tocilizumab in COVID Pneumonia CRP Level May Help Guide Use of Tocilizumab in COVID Pneumonia
It ' s worth considering tocilizumab in patients with moderate-to-severe COVID-19-associated pneumonia and high CRP levels, according to follow-up data from a randomized controlled trial.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - May 26, 2021 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

Arthritis drug can prevent COVID-19 deaths in the most serious patients, study finds 
Tocilizumab, a drug used to treat arthritis, may be effective in treating COVID-19 as well. Data shows that the drug can lead to better outcomes when used in high dosages. (Source: the Mail online | Health)
Source: the Mail online | Health - May 24, 2021 Category: Consumer Health News Source Type: news

Effectiveness of tocilizumab in patients hospitalized with COVID-19
(JAMA Network)What The Study Did:This follow-up study of a randomized clinical trial examines the association between survival and C-reactive protein levels in patients hospitalized with COVID-19 who were treated with tocilizumab. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 24, 2021 Category: Infectious Diseases Source Type: news

Covid-19: Key drugs, steroids in short supply; input costs surge
Two anti-virals — Remdesivir and Favipiravir — and Tocilizumab injections being used in the Covid-19 treatment have witnessed massive shortages over the last few months. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 21, 2021 Category: Pharmaceuticals Source Type: news

Delhi HC asks Centre to hold meeting with Roche to ensure immediate supply of Tocilizumab
Justice Prathiba M Singh said the officials of the ministry and the department shall hold a meeting with representatives of Roche India and its distributors here "to communicate and assess the demand for this drug in India". (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 7, 2021 Category: Pharmaceuticals Source Type: news

Government in no rush to grant 'compulsory licences'
Amid suggestions to use the tool for Remdisivir and Tocilizumab, two drugs that are being used, government sources said that it made little sense to invoke compulsory licensing provisions, given that the active pharmaceutical ingredient (API) is not available in the country. (Source: The Economic Times)
Source: The Economic Times - May 7, 2021 Category: Consumer Health News Source Type: news

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, The Lancet
In patients with hypoxia and evidence of systemic inflammation (C-reactive protein ≥75 mg/L), the addition of tocilizumab to usual standard of care (82% receiving systemic corticosteroids) reduced 28-day mortality (31% v 35%; rate ratio 0.85; 95% CI 0.76–0.94; p=0.0028). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 4, 2021 Category: Consumer Health News Source Type: news

Vision Loss in Giant Cell Arteritis Treated With Tocilizumab Vision Loss in Giant Cell Arteritis Treated With Tocilizumab
A new study examines the incidence of vision loss among patients with giant cell arteritis during treatment with tocilizumab compared with conventional glucocorticoid therapy.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 30, 2021 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Novartis signs initial agreement to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient for Roche's Actemra/RoActemra ®
Novartis has signed an initial agreement with Roche to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient (API) for Roche's Actemra/RoActemra® (tocilizumab), a treatment for rheumatoid arthritis which is also being tested in various clinical trials investigating the safety and efficacy in COVID-19 associated pneumonia. (Source: World Pharma News)
Source: World Pharma News - April 29, 2021 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Private hospitals to get remdesivir and tocilizumab through state governments
Private hospitals won ’t be able to procure remdesivir and tocilizumab required for Covid-19 treatment directly from manufacturers and will have to get them based on quotas set by state governments, which will, in turn, get them from the Centre. (Source: The Economic Times)
Source: The Economic Times - April 29, 2021 Category: Consumer Health News Source Type: news